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Abstract: (1) Background: The replacement of diets high in saturated fat (SAFA) with monounsat-
urated fatty acids (MUFA) is associated with better cardiovascular function and is related to the
modulation of the activity of the local renin–angiotensin system (RAS) and the collagenase activity of
dipeptidyl peptidase IV (DPP-IV). The objective of the work was to verify the capacity of different
types of dietary fat on the regulatory activities of RAS and DPP-IV. (2) Methods: Male Wistar rats
were fed for 24 weeks with three different diets: the standard diet (S), the standard diet supplemented
with virgin olive oil (20%) (VOO), or with butter (20%) plus cholesterol (0.1%) (Bch). The proteolytic
activities were determined by fluorometric methods in the soluble (sol) and membrane-bound (mb)
fractions of the left ventricle and atrium, aorta, and plasma samples. (3) Results: With the VOO
diet, angiotensinase values were significantly lower than with the Bch diet in the aorta (GluAP and
ArgAP (mb)), ventricle (ArgAP (mb)) and atrium (CysAP (sol)). Significant decreases in DPP-IV (mb)
activity occurred with the Bch diet in the atrium and aorta. The VOO diet significantly reduced the
activity of the cardiac damage marker LeuAP (mb) in the ventricle and aorta, except for LeuAP (sol)
in the ventricle, which was reduced with the Bch diet. (4) Conclusions: The introduction into the
diet of a source rich in MUFA would have a beneficial cardiovascular effect on RAS homeostasis and
cardiovascular functional stability.
Keywords: aminopeptidase activities; angiotensinases; dipeptidyl peptidase IV; high-fat diet; virgin
olive oil
1. Introduction
The high consumption of a high-fat diet (HFD) has been associated with most of the
epidemiological evidence during the last decades, especially the sources of saturated fatty
acids (SAFA) and cholesterol have been associated with an increased risk of suffering a
series of medical conditions such as obesity, diabetes, metabolic syndrome (MetS), and car-
diovascular diseases (CVD); however, these results do not extend to other types of lipid
sources [1]. HFD is a cardiac stressor that alters the expression of specific cardiac factors
due to glycolipotoxicity [2] and modifies cardiac structure and function. However, trials
involving the Mediterranean diet indicate that monounsaturated fatty acids (MUFAs) are
more effective than low-fat and low-cholesterol diets in preventing cardiovascular mortality
and coronary artery disease [3]. The reduction in SAFA in substitution by MUFA attenuates
the increase in blood pressure (BP) [4]. These alterations, depending on the degree of fatty
acid saturation, are related to changes in the systemic or local renin–angiotensin systems
(RAS) [5–10]. The activation of the RAS participates in the development of MetS, heart fail-
ure [11], and pathophysiology of hypertension [4,7,12–25]. Within these local RAS, the type of
fatty acids consumed with the diet allows modifying various enzymes of the aminopeptidase
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(AP) family, also called angiotensinases, responsible for metabolizing angiotensin peptides
(Ang) [5,9,26]. The APs are relevant in the control of BP and cardiac function [6,27], par-
ticipating in the regulation of systemic and local RAS, but also as predictive biomarkers of
functionality in different organs, including the heart [28–35]. It is suggested that several of the
activities of APs involved in the metabolism of angiotensin in the cardiovascular tissues of
the rat can be modified according to the amount and type of fat in the diet [6]. Among them,
the activity of aspartyl-AP (AspAP; EC 3.4.11.21) is responsible for the metabolism of Ang I to
Ang 2–10; glutamyl-AP (GluAP or aminopeptidase A, APA; EC 3.4.11.7) metabolizes Ang II
into Ang III; alanyl-AP (AlaAP or aminopeptidase M, APM; EC 3.4.11.2) and/or arginyl-AP
(ArgAP or aminopeptidase B, APB; EC 3.4.11.6) are responsible for the metabolism of Ang III
to Ang IV and Ang 4–8; and insulin-regulated AP (IRAP; 3.4.11.3)—also called AP-placental
leucyl (LAP), cystinyl-AP (CysAP), oxytokinase, or vasopressinase—was identified as the
binding site for the Ang IV receptor (AT4) [12,29,36–39].
Ang II and aldosterone are produced de novo within cardiac tissue [40,41]. RAS acti-
vation by diets high in SAFA induces CVD through the manifestation of oxidative stress,
inflammation, interstitial fibrosis at sites of vascular injury, ultrastructural abnormalities,
and diastolic dysfunction [42,43]. Hemodynamic factors regulate the growth of cardiomy-
ocytes, whereas reactive fibrosis is independent of blood pressure [40]. Under physiological
conditions the fibroblasts of the cardiac interstitium explain the gradual turnover of col-
lagen for a correct remodeling of the heart, but an alteration of the RAS would modify
the balance between the restructuring behavior [43,44] and collagen degradation [45,46].
Certain APs with broad specificity affect collagen production in cardiac fibroblasts [47].
Dipeptidyl-peptidase IV (DPP-IV; EC 3.4.14.5), also known as collagenase-like peptidase, is
a ubiquitously expressed serine-type aminopeptidase enzyme, with subsequent cleavage
at the N-terminal amino acids proline and alanine (X-Pro and X-Ala), and also metabolizes
the insulinotropic hormone glucagon-like peptide-1 (GLP-1) [48–50]. DPP-IV manifests
itself on the surface of vascular endothelial cells and in renovascular organs, suggesting a
role for DPP-IV in renal and cardiovascular function [51,52], in addition to being associated
with ECV [53,54]. The cardiac fibroblast migration and expressions of genes related to
fibrosis, such as collagen-I and transforming growth factor-β1 (TGF-β1), are suppressed
with a DPP-IV inhibitor [42,55], which, in turn, inhibits MR-dependent oxidative stress and
collagen induction mediated by aldosterone.
Thyrotropin-releasing hormone (TRH) has also been identified in the heart and
aorta [56], where it can modulate cardiovascular function, either autocrine or paracrine.
The enzyme pyroglutamyl-AP (pGluAP; EC 3.4.11.8) is known for its thyrotropin-releasing
hormone (TRH) degradation activity [18]. Previous results suggest that the type of fat
used in the diet can influence the local activity of pGluAP and modify its biological func-
tions in energy metabolism [4,9,57]. However, its effect on cardiovascular tissues is not
entirely clear.
Along with angiotensinases, there are other APs such as leucyl-AP (LeuAP; EC 3.4.11.1)
and gamma-glutamyl transferase (GGT; EC 2.3.2.2) involved in the control of BP that act
as functional markers of cardiovascular risk [7,9,58] and that are associated with different
cardiovascular and kidney diseases [34,54]. GGT is an enzyme of glutathione and cysteine
(Cys) metabolism with pro-oxidant activity and a modulating influence on endothelial
dysfunction [59]. Elevation of GGT levels is associated with an increased risk of cardiovas-
cular and metabolic diseases [59–62]. GGT is associated with an increase in mortality from
chronic heart disease events such as hypertension and congestive heart failure [28,31,63,64].
The main objectives of the current research were to understand the role of two types
of diets with higher MUFA or SAFA fat content on the angiotensinase activities that
regulate the classic and non-classic RAS pathways, to identify the implications for DPP-IV
collagenase activity, and to verify in each dietary group if there is an inter-relationship
between DPP-IV activities and angiotensinases in cardiovascular tissues. Measuring the
activities of GGT and LeuAP biomarkers and the degrading activity of TRH (pGluAP)
would make it possible to know the functional and metabolic state of cardiovascular tissues.
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We hypothesized that the inclusion of MUFA in the diet could be a preventive dietary factor
for reducing the activation of the RAS pathway through angiotensinases and maintaining
the functional integrity of cardiovascular structures.
2. Materials and Methods
2.1. Animals and Diets
Harlan Interfauna Ibérica SA (Barcelona, Spain) supplied adult male Wistar rats for
experimentation. The experimental procedures for the use and care of animals were carried
out in accordance with Directive 2010/63/EU of the Council of the European Communities
and Spanish Regulation RD 53/2013, being previously approved by the Institutional
Committee for Animal Use and Care of the University of Jaén with project code number
PIUJA_2005_acción 14 (1 January 2006). The rats had the experimental diets and water
ad libitum for 24 weeks and were kept under a controlled environment of temperature
(20–25 ◦C) and humidity (50 ± 5%) in a 12 h:12 h light/dark cycle. At the start of the
research, the animals were 6 months old and had an average body weight of ± 495 g. The
rats were randomly assigned into three experimental groups: (1) A standard diet (S, n = 6),
where the rats were fed with commercial food for laboratory rodents (Panlab, Barcelona,
Spain) whose nutritional composition was 16.5% protein, 3% total fat, 60% carbohydrates
(nitrogen-free extract (NFE)), 5% minerals, and 4% fiber. The other two diets were high
in fat (HFD), but with different fatty acid composition. (2) A group of rats was fed diet S
supplemented with 20% virgin olive oil (Cooperativa de los Villares, Jaén, Spain) (VOO,
n = 5), composed of a total content (%) of 75.5%ω-9-monounsaturated fatty acid (oleic acid,
C18:1), 11.5% saturated fatty acid (palmitic acid, C16:0), and 7.5% ω-6-polyunsaturated
fatty acid (linoleic acid, C18:2). (3) The second group of rats was fed diet S supplemented
with 20% butter (Hacendado, Valencia, Spain) plus cholesterol (0.1%) (Bch, n = 5), composed
of a total content (%) of 29% monounsaturated fatty acid (C18:1), 62% saturated fatty acid
(C16:0 and C18:0), 4% polyunsaturated fatty acid (C16:0), and short and medium chain
fatty acids (C4–C14). The Bch diet was supplemented with cholesterol (0.1%) in order to
reach the average cholesterol content of the Western diet. The HFD diets were isocaloric
among themselves (VOO diet, 1848 KJ/100 g; diet Bch, 1827 KJ/100 g) and hypercaloric
compared with the S diet (1392 KJ/100 g).
At the end of the experimental period, the animals were perfused with a saline solu-
tion (0.9% NaCl) through the left heart ventricle under Equithensin anesthesia (2 mL/kg
of body weight). A blood sample dissolved in heparin was previously extracted and
centrifuged for 10 min at 2000× g to obtain plasma. The heart and aorta were dissected,
immediately deposited in liquid nitrogen to separate the samples into different parts as
previously described [21], and frozen at −80 ◦C until use. The atrium and left ventricle
were dissected from the heart. The aorta was obtained by cutting from the aortic arch to its
abdominal portion.
2.2. Assay of Aminopeptidase Activities
Tissue samples were homogenized in 10 volumes of 10 mM Tris-HCl buffer (pH 7.4)
and ultracentrifuged at 100,000× g for 30 min at 4 ◦C. Analysis of enzyme activities and
protein content of the fraction soluble were performed with the supernatant and analyzed
in triplicate. The pellets were rehomogenized in 10 mM Tris-HCl buffer (pH 7.4) with 1%
Triton-X-100 to solubilize the membrane proteins and ultracentrifuged at 100,000× g for
30 min at 4 ◦C. The supernatants were kept for at least 4 h at 4 ◦C and shaken with SM-2
biobeads (100 mg/mL) (Bio-Rad, Richmond, VA, USA) to remove the detergent. Analyses
of enzyme activities and protein content of the membrane-bound fraction were conducted
with the resulting samples, analyzed also in triplicate.
The enzymatic activities of the soluble (sol) and membrane-bound (mb) fractions of
AlaAP, ArgAP, AspAP, CysAP/IRAP, DPP-IV, GGT, GluAP, LeuAP, and pGluAP were
measured by a fluorometric analysis using as aminoacyl-β-naphthylamides (aa-β-NA)
substrates: L-Ala-β-NA, L-Arg-β-NA, L-Asp-β-NA, L-Cys-β-NA, L-Gly-Pro-β-NA, G-
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Glu-β-NA, L-Glu-β-NA, L-Leu-β-NA, and L-pGlu-β-NA, respectively, according to the
methods of different authors [65–67] modified by Prieto and Ramírez [15,68]. An amount
of 10 µL/well of the supernatant sample was pipetted in 96-well black plates and was
incubated for 30 min at 37 ◦C in 100 µL of substrate solutions. The enzymatic reactions
were then stopped by adding 100 µL of 0.1 M acetate buffer (pH 4.2). The β-NA released
as a result of the enzymatic activity was quantified fluorometrically at an emission of
412 nm with an excitation of 345 nm. The activities of each tissue fraction were expressed as
pmoles of L-Ala-β-NA, L-Arg-β-NA, L-Asp-β-NA, L-Cys-β-NA, L-Gly-Pro-β-NA, G-Glu-
β-NA, L-Glu-β-NA, L-Leu-β-NA, and L-pGlu-β-NA hydrolyzed per minute and per mg
of protein (pmol aa-β-NA/min/mg prot). For plasma, it was expressed as picomole per
minute and per milliliter (pmol aa-β-NA/min/mL). All chemical products were supplied
by Sigma-Aldrich (St. Louis, MO, USA).
2.3. Protein Measurement
For protein quantification, the Bradford method [69] was used, using as standard a
bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO, USA) standard line.
2.4. Statistical Analysis
Statistical analysis was performed using one-way ANOVA, followed by Tukey’s
post hoc test for multiple comparisons. When the normality test failed, a Kruskal–Wallis
unidirectional range analysis of variance was performed. Pearson’s correlation coefficient
was used to establish the relationship between the APs activities of cardiovascular tissues
and plasma. Significant differences were estimated with Sigmaplot v11.0 software (Systat
Software, Inc., San José, CA, USA), and p-values less than 0.05 (p < 0.05) were considered
statistically significant. All data are presented as mean ± standard error of the mean (SEM).
3. Results
3.1. Angiotensinase Activities
To know how the type of fat in the diet affected the angiotensinase activities that were
derived from the classic RAS route, the activities that were studied are represented in the
following scheme in green, following the order of action of each angiotensinase based on
its precursors and metabolic products (Figure 1).
The values of all angiotensinase activities can be consulted in Supplementary Table S1.
None of the angiotensinase activities were significant in plasma. No significant differences
were observed in any of the tissues analyzed for AspAP and AlaAP activities. Furthermore,
the AspAP activity in the soluble fractions of the atrium and aorta was undetectable. The
VOO diet had significantly lower values than the Bch diet for the activities GluAP (mb) and
ArgAP (mb) in the aorta (GluAP (mb), VOO: 2024.36 ± 420.28 vs. Bch: 3986.00 ± 582.40;
ArgAP (mb), VOO: 1548.75 ± 129.86 vs. Bch: 2087.72 ± 139.98), ArgAP (mb) in the
ventricle (VOO: 763.06 ± 15.88 vs. Bch: 1013.07 ± 56.57), and CysAP (sol) in the atrium
(VOO: 195.50 ± 23.11 vs. Bch: 310.75 ± 21.51) (Figure 2A,C–E). However, in the ventricle,
the ArgAP (sol) activity had a higher value with the VOO diet with respect to the Bch diet
(VOO: 255.20 ± 52.95 vs. 127.80 ± 17.60; Figure 2B). Furthermore, the Bch diet significantly
increased CysAP (sol) activity of the atrium compared with the S diet (S: 212.18 ± 32.74 vs.
Bch: 310.75 ± 21.51; Figure 2E).
Supplementary Figure S1 shows the detection of grouped data correlations for GluAP
(sol/mb) and ArgAP (mb) activities between the ventricle and aorta, for CysAP (mb)
activity between the aorta and atrium, and for AlaAP (sol) between the plasma and ventricle.
However, when the dietary groups were analyzed independently with a stratified analysis,
it was observed that the association was lost.
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activity of the enzyme, cleaving amino acids from the amino terminals. 
 
Figure 2. Mean values ± standard errors of significant (A) glutamyl aminopeptidase (GluAP), (B–D) arginyl aminopepti-
dase (ArgAP), (E) cystinyl aminopeptidase (CysAP) activities in soluble (sol) and membrane-bound (mb) fractions of 
atrium, ventricle, and aorta. The small colored dots are data points per group. Values are expressed as pmol/min/mg prot 
in the rest of the tissues analyzed. * indicates significant differences between virgin olive oil diet (VOO) or butter plus 
cholesterol diet (Bch) vs. standard diet (S). * p < 0.05. # indicates significant differences between VOO and Bch, # p < 0.05. 
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3.2. Dipeptidyl Peptidase IV Activity
All values of DPP-IV activity can be found in Supplementary Table S2. Collagenase
activity of DPP-IV showed significant changes with HFDs in the atrium and aorta (Figure 3).
The atrium had higher values of DPP-IV activity (mb) in the VOO diet than in the Bch diet
(VOO: 1743.86 ± 99.46 vs. Bch: 1222.50 ± 223.93; Figure 3A). On the other hand, in the aorta,
the Bch diet reduced the DPP-IV activity (mb) with respect to the S diet (S: 3937.62 ± 478.42
vs. Bch: 2321.89 ± 224.54; Figure 3B). Despite a positive group correlation with all the data
for DPP-IV (sol) activity between aorta and plasma, the stratified correlations did not show
significance for independent groups (Supplementary Figure S2).
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3.3. Leucyl Aminopeptidase, Gamma-Glutamyl Transferase, and Pyroglutamyl
Aminopeptidase Activities
All values of LeuAP, GGT, and pGluAP activities can be found in Supplementary Table
S3. Activity levels in the atrium were undetectable for LeuAP (sol/mb), GGT (sol/mb), and
pGluAP (mb) activities. The GGT activity did not show that they were regulated by the
different HFDs in the different samples examined. The VOO diet presented significantly
lower LeuAP (mb) activity values than the Bch diet in the ventricle (VOO: 667.32 ± 23.08 vs.
Bch: 924.99 ± 39.31; Figure 4B) and aorta (VOO: 1753.36 ± 213.53 vs. Bch: 2681.70 ± 111.30;
Figure 4C). In turn, the Bch diet showed a significant increase in LeuAP (mb) activity
compared with the S diet (Figure 4B, S: 636.06 ± 70.51 vs. Bch: 924.99 ± 39.31; Figure 4C,
S: 2071.56 ± 100.69 vs. Bch: 2681.70 ± 111.30). On the contrary, LeuAP (sol) activity
was significantly reduced with the Bch diet in the ventricle (S: 291.37 ± 33.40 vs. Bch:
162.87 ± 21.53; Figure 4A). With all the point data, a significantly positive grouped corre-
lation was found between the LeuAP activity (mb) of the aorta and the ventricle, but a
stratified analysis by dietary groups (Supplementary Figure S3: intra-group correlations)
showed that LeuAP was not associated with diet. Furthermore, both HFDs showed a
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reduction in pGluAP (mb) activity only in the atrium (S: 75.99 ± 1.82; VOO: 58.22 ± 4.92;
Bch: 54.83 ± 6.00; Figure 4D).
Table 1. Significant correlations of dipeptidyl peptidase IV (DPP-IV) activity with angiotensinase activities in atrium,
ventricle, and aorta.
Sample DPP-IV (Fraction) Angiotensinase(Fraction) p-Value R
Intra-Group
Correlations p-Value R
Atrium DPP-IV (sol) vs.
AlaAP (sol) 0.004 0.692 VOO–VOO 0.007 0.969
ArgAP (sol) 0.002 0.734





Atrium DPP-IV (mb) vs.





ArgAP (mb) 0.012 0.609 S–S 0.011 0.912
CysAP (mb) 0.040 0.517
GluAP (mb) 0.037 0.526 S-S 0.006 0.936
Ventricle DPP-IV (sol) vs.





ArgAP (sol) <0.001 0.923 VOO–VOO 0.004 0.979





CysAP (sol) <0.001 0.756 VOO–VOO 0.023 0.929
GluAP (sol) <0.001 0.904 VOO–VOO 0.002 0.986
Aorta DPP-IV (sol) vs.
ArgAP (sol) 0.048 0.542
AlaAP (sol) 0.044 0.589
Aorta DPP-IV (mb) vs. CysAP (mb) 0.019 0.638
Note: The values represent only those significant correlations between tissues. Values represent correlation of dipeptidyl peptidase IV vs.
angiotensinases activities, in soluble (sol) and membrane-bound (mb) fractions of atrium, ventricle, and aorta. Intra-group correlations
analyze the correlations between activities of the same dietary group. AlaAP: alanyl aminopeptidase; ArgAP: arginyl aminopeptidase;
AspAP: aspartyl aminopeptidase; CysAP: cistinyl aminopeptidase; GluAP: glutamyl aminopeptidase; DPP-IV: dipeptidyl peptidase IV.
p-value less than 0.05 was considered significant. R: linear correlation coefficient.
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4. Discussion
Adequate nutritional status is essential for maintaining cardiovascular structure and
functionality in the face of metabolic challenges [2,70]. During the last decade, there has
been intensive debate about the advice to reduce SAFA and increase MUFA or polyunsat-
urated (PUFA) to reduce the risk of CVD [71,72]. Virgin olive oil has a preventive effect
on the development of atherosclerosis, indicating that endothelial damage triggered by
oxidation can be diminished or reversed by the compounds of olive oil [73,74]. In recent
work in our laboratory using the same HFDs (VOO and Bch), we confirmed the beneficial
effects in animals fed the VOO diet vs. the pernicious results with the Bch diet. With the
VOO diet, they do not increase their body weight, they do not increase the values of systolic
blood pressure (SBP), and they maintain normal values of triglycerides and the fraction of
VLDL cholesterol, reduce total cholesterol and its LDL fraction, and reduce oxidative stress
and lipid peroxidation against the pernicious effects that the Bch diet manifests. [4,7,9].
Elevated plasma cholesterol levels are another important risk factor widely recognized for
its relationship with angiotensin metabolism [4,5,7,10,12,72], with Mediterranean countries
showing lower rates of heart disease than other countries due to the usual diet rich in olive
oil [75].
HFDs alter the baroreceptor reflex [76], and the type of fatty acid that makes up the
diet is capable of modulating the central [10,26,77] and local RAS regulatory APs [4,5,7,9,57].
Our results show that the VOO diet favored the stabilization of the RAS with respect to the
Bch diet, by lowering the values of GluAP (mb) activities in the aorta, ArgAP (mb) in the
ventricle and aorta, and CysAP (mb) in the atrium. In turn, it was observed in the ventricle
that CysAP (mb) activity was significantly elevated with diet S in addition to VOO. These
data may have repercussions with previously published data, where they identified that the
local and serum mRNA and/or the activities of AspAP and GluAP progressively increase
with the degree of saturation of fatty acids in the diet [4,7,10,72]. GluAP activity is modified
by the composition of fatty acids in the diet and by the cholesterol content [4–6,9,57],
directly or indirectly, and with an important role in the development of cardiovascular
disorders and the pathophysiology of hypertension. An analysis of grouped data showed
significant correlations of angiotensinase activities in various cardiovascular tissues and
plasma (Supplementary Figure S1); however, a stratified analysis isolating dietary groups
showed that angiotensinase activities were not associated with each group of diets and
that they were not associated with the type of fat used. This absence of correlations does
not agree with other studies in which they showed the impact of the fatty acid profile of
the diet on central tissues and its correlation with APs activities [26,77]. It is demonstrated
that the profile of fatty acids and the levels of APs activities are modified depending on the
type of fat used [77], and their activities correlate with dietary fat composition [7,26].
The cardiac interstitium is made up of non-myocytic cells embedded in a highly
organized extracellular matrix that contains a three-dimensional collagen network that
serves to maintain the architecture of the myocardium and determine its rigidity [78]. It is
known that circulating and myocardial cells RAS are directly involved in the regulation
of cardiac interstitial remodeling. Oleic acid (n-9), a component of olive oil, prevents Ang
II-induced cardiac remodeling (fibrosis and hypertrophy) by suppressing the expression of
collagen and fibroblast growth factor 23 (FGF23) in mice [79]. GluAP inhibitors and Ang
IV analogs prevent cardiac dysfunction by normalizing central/local GluAP hyperactivity
and attenuating cardiac hypertrophy and fibrosis [27,80,81]. Our results show that together
with the marked decrease in the RAS activity of the VOO diet compared with the Bch
diet, in addition, the VOO diet presented normal values of DPP-IV activity (mb) in the
atrium and aorta, but they were significantly lower with the diet Bch. In summary, our data
showed higher values of RAS regulatory activities together with lower values of DPP-IV
with the Bch diet; these data coincide with investigations that reveal that Ang II stimulates
collagen synthesis and inhibits collagenase activity in cardiac fibroblasts [78,82,83]. In
a contradictory way, other researchers confirm that HFD with a high content of SAFA
increases the expression and activity of DPP-IV in the aorta and atrium, playing a role
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in the development of aortic stiffness, vascular oxidative stress, endothelial dysfunction,
and vascular remodeling by promoting increased deposition of collagen fibers [84–86].
The grouped correlation between DPP-IV and angiotensinases activities in cardiovascular
tissues (Table 1) manifested a strong association with collagenase DPP-IV activity when the
classical and non-classical pathways of RAS were activated. A stratified analysis between
independent groups confirmed the association of activities with the variable diet. These
results are interesting because it was determined that olive oil has an important role in
the association of regulatory activities of RAS (AlaAP, ArgAP, AspAP, CysAP, GluAP) and
DPP-IV activity in the atrium and ventricle (Table 1). Second, as we have commented
previously, the VOO diet detected in the atrium the lowest values of CysAP activity and
normal values of DPP-IV activity compared with the Bch diet. However, the atrium showed
a marked increase in CysAP activity with diet Bch compared with diet S and lower values of
DPP-IV activity with diet Bch versus diet VOO. Without going further, strong correlations
of grouped data were detected between DPP-IV and CysAP activities in all tissues (Table 1),
where a stratified analysis showed that the VOO diet was a variable that affected this
association in the atrium and ventricle. These results make sense since it is known that
there is an interaction of CysAP with DPP-IV that acts in the pathway of the kinin system
(metabolism of bradykinin) as a counter-regulation of an overactivation of the RAS [87]. In
non-cardiovascular tissues with fibrosis, they are also represented by inflammation and a
deposit of cellular matrix, where DPP-IV has a profibrotic role of binding to fibronectin,
influencing cell adhesion and migration [88,89].
With the VOO diet vs. the Bch diet, in the ventricular and aortic membrane-bound
fractions, the lower values of GluAP and ArgAP angiotensinase activities allowed less
arterial damage, as reflected by the activity of the functional marker LeuAP. The LeuAP
(mb) activity was elevated in aorta with the Bch diet compared with the S diet; however,
the VOO diet showed its benefit by maintaining the LeuAP activity at normal values.
Similar results were found in another vascularized organ model using the same type of
experimental diets [9]. Our experimental diets did not show significant GGT activity in
the cardiovascular tissue fractions; therefore, it does not indicate increased oxidative stress
or insufficient oxidation. These results are totally contradictory to the values found in
different vascularized organs of animals treated with the same experimental diets, where
the VOO diet had lower values than the Bch diet, even behaving as its control [7,9].
The pGluAP (mb) activity was significantly reduced in the atrium with both HFDs
with respect to diet S. These data do not agree with other results, where a significant
increase in pGluAP (sol/mb) activity of the atrium has been described in renovascular
hypertension; however, in the aorta, there are no differences, and in the ventricle, the
activity is reduced without being significant with respect to its healthy controls [17]. These
differences are probably due to the differences between the animal models.
Treatment of hypertension with AP inhibitors [4,5] has not been shown to totally
prevent CVD outcomes [90,91]. Angiotensinases and DPP-IV are objects of study to find
new therapeutic approaches targeting RAS and associated peptides in hypertension and
heart failure [87]. However, prevention with diets enriched with olive oil has an important
influence on the reduction in the central and local RAS pathway [6,7,9,10]. Our results
also showed lower angiotensinase activity values with the VOO diet compared with the
Bch diet. A main limitation of our study is that the actions of HFDs can be different
depending on many variables, such as the species and animal model used, as well as
depending on the multiple components of the diet itself; therefore, these experiments
cannot be transferred to humans. Adding to that accentuation of the effects of RAS, the
experiments were started with adult animals (6 months of age), and the experimental
diets were continued with 6-month follow-up. The older age among the animals used
in the experiment and the small size of the samples (n = 6–5/group) can increase the
variability in the parameters studied and contribute to reducing the differences observed
between the groups. Additional research on components of olive oil should be conducted
in new preclinical models associated with CDV. In addition, it should be determined in
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more detail if the cardiovascular benefits of olive oil derive from saponifiable lipids or
non-saponifiable lipids, which are minor components, such as phenolic compounds with
antioxidant character. For this, it is proposed to try a pure diet in MUFA (refined virgin
olive oil) or extracts of olive leaves rich in polyphenols.
5. Conclusions
All the results predicted a differential effect of two high-fat diets on RAS regulation,
functionality, and stability in the atrium, ventricle, and aorta (Figure 5). The inclusion of
virgin olive oil in the diets moderated the normalization of RAS activities in the atrium
(CysAP), ventricle (GluAP and ArgAP), and aorta (GluAP and ArgAP). However, the Bch
diet had a significant increase in CysAP activity in the atrium, together with increases
in the activity of functional marker LeuAP in the ventricle and aorta, while the olive oil
normalized the LeuAP values. The VOO diet showed normal DPP-IV activity; however,
the Bch diet reduced DPP-IV activity in the aorta. Interestingly, DPP-IV and angiotensinase
activities were strongly correlated intragroup, especially with the VOO diet for AlaAP,
ArgAP, AspAP, CysAP, and GluAP activities in the atrium ventricle. The replacement of
saturated fats with monounsaturated fats would benefit by normalizing the activities that
regulate homeostasis of the classical and non-classical pathways of RAS and DPP-IV for
proper maintenance and functioning of the cardiovascular system.
Biomedicines 2021, 9, x FOR PEER REVIEW 11 of 17 
 
 
Figure 5. (A) Summary of the influence of the type of fat in the diet on the regulatory activities of the renin–angiotensin 
system, cardiac biomarker leucine aminopeptidase, and dipeptidyl peptidase IV. ArgAP: arginyl aminopeptidase; CysAP: 
cystinyl aminopeptidase; DPP-IV: dipeptidyl peptidase IV; GluAP: glutamyl aminopeptidase; LeuAP: leucyl aminopepti-
dase; pGluAP: pyroglutamyl aminopeptidase. VOO: diet enriched with virgin olive oil; Bch: diet enriched with butter plus 
cholesterol. (B) Differences in cardiovascular physiology with a long-term Mediterranean diet or Western diet at the struc-
tural or functional level in the heart and aorta. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: 
Group and intra-group correlations between significant glutamyl aminopeptidase, alanyl ami-
nopeptidase, arginyl aminopeptidase, and cystinyl aminopeptidase activities analyzed in plasma 
Figure 5. Cont.
Biomedicines 2021, 9, 1149 11 of 16
Biomedicines 2021, 9, x FOR PEER REVIEW 11 of 17 
 
 
Figure 5. (A) Summary of the influence of the type of fat in the diet on the regulatory activities of the renin–angiotensin 
system, cardiac biomarker leucine aminopeptidase, and dipeptidyl peptidase IV. ArgAP: arginyl aminopeptidase; CysAP: 
cystinyl aminopeptidase; DPP-IV: dipeptidyl peptidase IV; GluAP: glutamyl aminopeptidase; LeuAP: leucyl aminopepti-
dase; pGluAP: pyroglutamyl aminopeptidase. VOO: diet enriched with virgin olive oil; Bch: diet enriched with butter plus 
cholesterol. (B) Differences in cardiovascular physiology with a long-term Mediterranean diet or Western diet at the struc-
tural or functional level in the heart and aorta. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: 
Group and intra-group correlations between significant glutamyl aminopeptidase, alanyl ami-
nopeptidase, arginyl aminopeptidase, and cystinyl aminopeptidase activities analyzed in plasma 
Figure 5. (A) Summary of the influence of the type of fat in the diet on the regulatory activities of the renin–angiotensin
system, cardiac biomarker leucine aminopeptidase, and dipeptidyl peptidase IV. ArgAP: arginyl aminopeptidase; CysAP:
cystinyl aminopeptidase; DPP-IV: dipeptidyl peptidase IV; GluAP: glutamyl aminopeptidase; LeuAP: leucyl aminopeptidase;
pGluAP: pyroglutamyl aminopeptidase. VOO: diet enriched with virgin olive oil; Bch: diet enriched with butter plus
cholesterol. (B) Differences in cardiovascular physiology with a long-term Mediterranean diet or Western diet at the
structural or functional level in the heart and aorta.
Suppleme tary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/biomedicines9091149/s1, Figure S1: Group and intra-group correlations betwee significant
glutamyl aminopeptidase, alanyl aminopeptidase, arginyl aminopeptidase, and cystinyl aminopepti-
dase activities analyzed in plasma and soluble and membrane-bound fractions of atrium, ventricle
and aorta, Figure S2: Group and intra-group correlations between significant dipeptidyl peptidase
IV activity analyzed in plasma and soluble fractions of atrium, Figure S3: Group and intra-group
correlations between significant leucyl aminopeptidase activity analyzed in membrane-bound frac-
tions of ventricle and aorta, Table S1: Angiotensinase activities in atrium, ventricle, aorta and plasma,
Table S2: Dipeptidyl dipeptidase IV activity in atrium, ventricle, aorta and plasma, Table S3: Leucyl
aminopeptidase, gamma-glutamyl transferase and pyroglutamyl aminopeptidase activities in atrium,
ventricle, aorta and plasma.
Author Contributions: Conceptualization, I.P., M.R.-S., and G.D.-V.; methodology, I.P., A.B.S., and
G.D.-V.; investigation, I.P., A.B.S., and G.D.-V.; data curation, A.B.S. and G.D.-V.; writing—original
draft preparation, I.P. and G.D.-V.; writing—review and editing, I.P. and G.D.-V.; supervision, I.P.,
G.D.-V., and M.R.-S.; project administration, I.P.; funding acquisition, I.P. All authors have read and
agreed to the published version of the manuscript.
Funding: This work was supported by grant code: ACCIÓN 1 PAIUJA 2019 2020: BIO221.
Institutional Review Board Statement: The study was conducted according to the guidelines of
the Declaration of Helsinki, and the study was approved by the Institutional Animal Care and Use
Committee of the University of Jaén (project number P.I.UJA_2005_acción 14), of the University of
Jaén. Technical and human support provided by Recursos Científicos-Técnicos (CICT) Universidad
de Jaén (UJA), Ministerio de Economía, Industria y Competitividad (MINECO), Junta de Andalucía,
and Fondo Europeo de Desarrollo Regional (FEDER) is gratefully acknowledged.
Informed Consent Statement: Not applicable.
Biomedicines 2021, 9, 1149 12 of 16
Data Availability Statement: Not applicable.
Acknowledgments: The authors would like to acknowledge the technical and human support
provided by CICT and CEPA of the Universidad de Jaén (UJA, MINECO, Junta de Andalucía; FEDER).





















SAFA saturated fatty acids
VOO virgin olive oil
References
1. Vasilopoulou, D.; Markey, O.; Kliem, K.E.; Fagan, C.C.; Grandison, A.S.; Humphries, D.J.; Todd, S.; Jackson, K.G.; Givens, D.I.;
Lovegrove, J.A. Reformulation initiative for partial replacement of saturated with unsaturated fats in dairy foods attenuates
the increase in LDL cholesterol and improves flow-mediated dilatation compared with conventional dairy: The randomized,
controlled REplacement of SaturatEd fat in dairy on Total cholesterol (RESET) study. Am. J. Clin. Nutr. 2020, 111, 739–748.
[CrossRef]
2. Cerf, M.E. High Fat Programming and Cardiovascular Disease. Medicina 2018, 54, 86. [CrossRef]
3. Wali, J.A.; Jarzebska, N.; Raubenheimer, D.; Simpson, S.J.; Rodionov, R.N.; O’Sullivan, J.F. Cardio-Metabolic Effects of High-Fat
Diets and Their Underlying Mechanisms—A Narrative Review. Nutrients 2020, 12, 1505. [CrossRef] [PubMed]
4. Domínguez-Vías, G.; Segarra, A.B.; Ramírez-Sánchez, M.; Prieto, I. Effects of Virgin Olive Oil on Blood Pressure and Renal
Aminopeptidase Activities in Male Wistar Rats. Int. J. Mol. Sci. 2021, 22, 5388. [CrossRef] [PubMed]
5. Segarra, A.B.; Ramirez, M.; Banegas, I.; Alba, F.; Vives, F.; Gasparo, M.d.; Ortega, E.; Ruiz, E.; Prieto, I. Dietary fat influences
testosterone, cholesterol, aminopeptidase A, and blood pressure in male rats. Horm. Metab. Res. 2008, 40, 289–291. [CrossRef]
6. Villarejo, A.B.; Ramírez-Sánchez, M.; Segarra, A.B.; Martínez-Cañamero, M.; Prieto, I. Influence of extra virgin olive oil on blood
pressure and kidney angiotensinase activities in spontaneously hypertensive rats. Planta Med. 2015, 81, 664–669. [CrossRef]
[PubMed]
7. Domínguez-Vías, G.; Segarra, A.B.; Martínez-Cañamero, M.; Ramírez-Sánchez, M.; Prieto, I. Influence of a Virgin Olive Oil versus
Butter Plus Cholesterol-Enriched Diet on Testicular Enzymatic Activities in Adult Male Rats. Int. J. Mol. Sci. 2017, 18, 1701.
[CrossRef]
8. Martínez, N.; Prieto, I.; Hidalgo, M.; Segarra, A.B.; Martínez-Rodríguez, A.M.; Cobo, A.; Ramírez, M.; Gálvez, A.;
Martínez-Cañamero, M. Refined versus Extra Virgin Olive Oil High-Fat Diet Impact on Intestinal Microbiota of Mice
and Its Relation to Different Physiological Variables. Microorganisms 2019, 7, 61. [CrossRef]
9. Domínguez-Vías, G.; Segarra, A.B.; Ramírez-Sánchez, M.; Prieto, I. The Role of High Fat Diets and Liver Peptidase Activity in the
Development of Obesity and Insulin Resistance in Wistar Rats. Nutrients 2020, 12, 636. [CrossRef] [PubMed]
10. Segarra, A.B.; Domínguez-Vías, G.; Redondo, J.; Martínez-Cañamero, M.; Ramírez-Sánchez, M.; Prieto, I. Hypothalamic Renin–
Angiotensin System and Lipid Metabolism: Effects of Virgin Olive Oil versus Butter in the Diet. Nutrients 2021, 13, 480. [CrossRef]
Biomedicines 2021, 9, 1149 13 of 16
11. Sánchez-Aguilar, M.; Ibarra-Lara, L.; Del Valle-Mondragón, L.; Soria-Castro, E.; Torres-Narváez, J.C.; Carreón-Torres, E.;
Sánchez-Mendoza, A.; Rubio-Ruíz, M.E. Nonclassical Axis of the Renin-Angiotensin System and Neprilysin: Key Mediators That
Underlie the Cardioprotective Effect of PPAR-Alpha Activation during Myocardial Ischemia in a Metabolic Syndrome Model.
PPAR Res. 2020, 2020, 8894525. [CrossRef] [PubMed]
12. Ramírez, M.; Prieto, I.; Alba, F.; Vives, F.; Banegas, I.; de Gasparo, M. Role of central and peripheral aminopeptidase activities in
the control of blood pressure: A working hypothesis. Heart Fail Rev. 2008, 13, 339–353. [CrossRef] [PubMed]
13. Ramírez, M.; Prieto, I.; Martinez, J.M.; Vargas, F.; Alba, F. Renal aminopeptidase activities in animal models of hypertension.
Regul. Pept. 1997, 72, 155–159. [CrossRef]
14. Prieto, I.; Martinez, A.; Martinez, J.M.; Ramírez, M.J.; Vargas, F.; Alba, F.; Ramírez, M. Activities of aminopeptidases in a rat saline
model of volume hypertension. Horm. Metab. Res. 1998, 30, 246–248. [CrossRef]
15. Prieto, I.; Martínez, J.M.; Hermoso, F.; Ramírez, M.J.; de Gasparo, M.; Vargas, F.; Alba, F.; Ramírez, M. Effect of valsartan on
angiotensin II- and vasopressin-degrading activities in the kidney of normotensive and hypertensive rats. Horm. Metab. Res. 2001,
33, 559–563. [CrossRef]
16. Prieto, I.; Arechaga, G.; Segarra, A.B.; Alba, F.; de Gasparo, M.; Ramirez, M. Effects of dehydration on renal aminopeptidase
activities in adult male and female rats. Regul. Pept. 2002, 106, 27–32. [CrossRef]
17. Prieto, I.; Hermoso, F.; de Gasparo, M.; Vargas, F.; Alba, F.; Segarra, A.B.; Banegas, I.; Ramírez, M. Aminopeptidase activity in
renovascular hypertension. Med. Sci. Monit. 2003, 9, 31–36.
18. Prieto, I.; Hermoso, F.; Gasparo, M.d.; Vargas, F.; Alba, F.; Segarra, A.B.; Banegas, I.; Ramírez, M. Angiotensinase activities in the
kidney of renovascular hypertensive rats. Peptides 2003, 24, 755–760. [CrossRef]
19. Segarra, A.B.; Prieto, I.; Villarejo, A.B.; Banegas, I.; Wangensteen, R.; de Gasparo, M.; Vives, F.; Ramírez-Sánchez, M. Effects of
antihypertensive drugs on angiotensinase activities in the testis of spontaneously hypertensive rats. Horm. Metab. Res. 2013, 45,
344–348. [CrossRef]
20. Prieto, I.; Villarejo, A.B.; Segarra, A.B.; Banegas, I.; Wangensteen, R.; Martinez-Cañamero, M.; de Gasparo, M.; Vives, F.; Ramírez-
Sánchez, M. Brain, heart and kidney correlate for the control of blood pressure and water balance: Role of angiotensinases.
Neuroendocrinology 2014, 100, 198–208. [CrossRef] [PubMed]
21. Villarejo, A.B.; Prieto, I.; Segarra, A.B.; Banegas, I.; Wangensteen, R.; Vives, F.; de Gasparo, M.; Ramírez-Sánchez, M. Relationship
of angiotensinase and vasopressinase activities between hypothalamus, heart, and plasma in L-NAME-treated WKY and SHR.
Horm. Metab. Res. 2014, 46, 561–567. [CrossRef] [PubMed]
22. Prieto, I.; Villarejo, A.B.; Segarra, A.B.; Wangensteen, R.; Banegas, I.; de Gasparo, M.; Vanderheyden, P.; Zorad, S.; Vives, F.;
Ramírez-Sánchez, M. Tissue distribution of CysAP activity and its relationship to blood pressure and water balance. Life Sci. 2015,
134, 73–78. [CrossRef] [PubMed]
23. Prieto, I.; Segarra, A.B.; de Gasparo, M.; Martínez-Cañamero, M.; Ramírez-Sánchez, M. Divergent profile between hypothalamic
and plasmatic aminopeptidase activities in WKY and SHR. Influence of beta-adrenergic blockade. Life Sci. 2018, 192, 9–17.
[CrossRef] [PubMed]
24. Keck, M.; Hmazzou, R.; Llorens-Cortes, C. Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future
Directions. Curr. Hypertens. Rep. 2019, 21, 50. [CrossRef] [PubMed]
25. Llorens-Cortes, C.; Touyz, R.M. Evolution of a New Class of Antihypertensive Drugs: Targeting the Brain Renin-Angiotensin
System. Hypertension 2020, 75, 6–15. [CrossRef]
26. Segarra, A.B.; Ruiz-Sanz, J.I.; Ruiz-Larrea, M.B.; Ramírez-Sánchez, M.; de Gasparo, M.; Banegas, I.; Martínez-Cañamero, M.;
Vives, F.; Prieto, I. The profile of fatty acids in frontal cortex of rats depends on the type of fat used in the diet and correlates with
neuropeptidase activities. Horm. Metab. Res. 2011, 43, 86–91. [CrossRef]
27. Boitard, S.E.; Marc, Y.; Keck, M.; Mougenot, N.; Agbulut, O.; Balavoine, F.; Llorens-Cortes, C. Brain renin-angiotensin system
blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice. J. Mol.
Cell Cardiol. 2019, 127, 215–222. [CrossRef]
28. Turgut, O.; Yilmaz, A.; Yalta, K.; Karadas, F.; Birhan-Yilmaz, M. Gamma-Glutamyltransferase is a promising biomarker for
cardiovascular risk. Med. Hypotheses. 2006, 67, 1060–1064. [CrossRef]
29. Danziger, R.S. Aminopeptidase N in arterial hypertension. Heart Fail. Rev. 2008, 13, 293–298. [CrossRef]
30. Tsujimoto, M.; Goto, Y.; Maruyama, M.; Hattori, A. Biochemical and enzymatic properties of the M1 family of aminopeptidases
involved in the regulation of blood pressure. Heart Fail Rev. 2008, 13, 285–291. [CrossRef]
31. Mason, J.E.; Starke, R.D.; Van Kirk, J.E. Gamma-glutamyl transferase: A novel cardiovascular risk biomarker. Prev. Cardiol. 2010,
13, 36–41. [CrossRef] [PubMed]
32. Quesada, A.; Vargas, F.; Montoro-Molina, S.; O’Valle, F.; Rodríguez-Martínez, M.D.; Osuna, A.; Prieto, I.; Ramírez, M.;
Wangensteen, R. Urinary aminopeptidase activities as early and predictive biomarkers of renal dysfunction in cisplatin-treated
rats. PLoS ONE 2012. [CrossRef] [PubMed]
33. Chai, Y.; Gao, Y.; Xiong, H.; Lv, W.; Yang, G.; Lu, C.; Nie, J.; Ma, C.; Chen, Z.; Ren, J.; et al. A near-infrared fluorescent probe for
monitoring leucine aminopeptidase in living cells. Analyst 2019, 144, 463–467. [CrossRef]
34. Vargas, F.; Wangesteen, R.; Rodríguez-Gómez, I.; García-Estañ, J. Aminopeptidases in Cardiovascular and Renal Function. Role
as Predictive Renal Injury Biomarkers. Int. J. Mol. Sci. 2020, 21, 5615. [CrossRef]
Biomedicines 2021, 9, 1149 14 of 16
35. Du, K.; Sheng, L.; Luo, X.; Fan, G.; Shen, D.; Wu, C.; Shen, R. A ratiometric fluorescent probe based on quinoline for monitoring
and imaging of Leucine aminopeptidase in liver tumor cells. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2021, 249, 119328.
[CrossRef] [PubMed]
36. Vauquelin, G.; Michotte, Y.; Smolders, I.; Sarre, S.; Ebinger, G.; Dupont, A.; Vanderheyden, P. Cellular targets for angiotensin II
fragments: Pharmacological and molecular evidence. J. Renin Angiotensin Aldosterone Syst. 2002, 3, 195–204. [CrossRef]
37. Wallis, M.G.; Lankford, M.F.; Keller, S.R. Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP.
Am. J. Physiol. Endocrinol. Metab. 2007, 293, 1092–1102. [CrossRef]
38. Ramírez-Sánchez, M.; Prieto, I.; Wangensteen, R.; Banegas, I.; Segarra, A.B.; Villarejo, A.B.; Vives, F.; Cobo, J.; de Gasparo, M. The
renin-angiotensin system: New insight into old therapies. Curr. Med. Chem. 2013, 20, 1313–1322. [CrossRef]
39. Segarra, A.B.; Prieto, I.; Martinez-Canamero, M.; Vargas, F.; De Gasparo, M.; Vanderheyden, P.; Zorad, S.; Ramirez-Sanchez, M.
Cystinyl and pyroglutamyl-beta-naphthylamide hydrolyzing activities are modified coordinately between hypothalamus, liver
and plasma depending on the thyroid status of adult male rats. J. Physiol. Pharmacol. 2018, 69, 197–204. [CrossRef]
40. Weber, K.T. Fibrosis and hypertensive heart disease. Curr. Opin. Cardiol. 2000, 15, 264–272. [CrossRef]
41. Weber, K.T. Fibrosis in hypertensive heart disease: Focus on cardiac fibroblasts. J. Hypertens. 2004, 22, 47–50. [CrossRef]
42. Aroor, A.R.; Habibi, J.; Kandikattu, H.K.; Garro-Kacher, M.; Barron, B.; Chen, D.; Hayden, M.R.; Whaley-Connell, A.; Bender, S.B.;
Klein, T.; et al. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2
expression, inflammation and fibrosis in female mice. Cardiovasc. Diabetol. 2017, 16, 61. [CrossRef] [PubMed]
43. Sun, Y.; Zhang, J.; Lu, L.; Chen, S.S.; Quinn, M.T.; Weber, K.T. Aldosterone-induced inflammation in the rat heart: Role of oxidative
stress. Am. J. Pathol. 2002, 161, 1773–1781. [CrossRef]
44. Li, C.; Han, R.; Kang, L.; Wang, J.; Gao, Y.; Li, Y.; He, J.; Tian, J. Pirfenidone controls the feedback loop of the AT1R/p38
MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis. Sci. Rep.
2017, 7, 40523. [CrossRef]
45. Laurent, G.J. Dynamic state of collagen: Pathways of collagen degradation in vivo and their possible role in regulation of collagen
mass. Am. J. Physiol. 1987, 252, 1–9. [CrossRef] [PubMed]
46. Wang, Y.; Kou, J.; Zhang, H.; Wang, C.; Li, H.; Ren, Y.; Zhang, Y. The renin-angiotensin system in the synovium promotes
periarticular osteopenia in a rat model of collagen-induced arthritis. Int. Immunopharmacol. 2018, 65, 550–558. [CrossRef]
47. Lijnen, P.J.; Petrov, V.V.; Fagard, R.H. Collagen production in cardiac fibroblasts during inhibition of angiotensin-converting
enzyme and aminopeptidases. J. Hypertens. 2004, 22, 209–216. [CrossRef]
48. Mizutani, T.; Mizutani, H.; Kaneda, T.; Hagihara, M.; Nagatsu, T. Activity of dipeptidyl peptidase II and dipeptidyl peptidase IV
in human gingiva with chronic marginal periodontitis. Arch. Oral Biol. 1990, 35, 891–894. [CrossRef]
49. Kamori, M.; Hagihara, M.; Nagatsu, T.; Iwata, H.; Miura, T. Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl
endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis.
Biochem. Med. Metab. Biol. 1991, 45, 154–160. [CrossRef]
50. Hatanaka, T.; Kawakami, K.; Uraji, M. Inhibitory effect of collagen-derived tripeptides on dipeptidylpeptidase-IV activity. J.
Enzyme Inhib. Med. Chem. 2014, 29, 823–828. [CrossRef]
51. Kenny, A.J.; Booth, A.G.; George, S.G.; Ingram, J.; Kershaw, D.; Wood, E.J.; Young, A.R. Dipeptidyl peptidase IV, a kidney
brush-border serine peptidase. Biochem. J. 1976, 157, 169–182. [CrossRef] [PubMed]
52. Nistala, R.; Savin, V. Diabetes, hypertension, and chronic kidney disease progression: Role of DPP4. Am. J. Physiol. Renal Physiol.
2017, 312, 661–670. [CrossRef]
53. Zhong, J.; Rao, X.; Rajagopalan, S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential
implications in cardiovascular disease. Atherosclerosis 2013, 226, 305–314. [CrossRef]
54. Wolke, C.; Teumer, A.; Endlich, K.; Endlich, N.; Rettig, R.; Stracke, S.; Fiene, B.; Aymanns, S.; Felix, S.B.; Hannemann, A.; et al.
Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort. Exp. Biol. Med. 2017, 242, 554–563.
[CrossRef] [PubMed]
55. Yamaguchi, T.; Watanabe, A.; Tanaka, M.; Shiota, M.; Osada-Oka, M.; Sano, S.; Yoshiyama, M.; Miura, K.; Kitajima, S.; Matsunaga,
S.; et al. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction
independently of DPP-4. J. Pharmacol. Sci. 2019, 139, 112–119. [CrossRef]
56. Shi, Z.X.; Xu, W.; Mergner, W.J.; Li, Q.L.; Cole, K.H.; Wilber, J.F. Localization of thyrotropin-releasing hormone mRNA expression
in the rat heart by in situ hybridization histochemistry. Pathobiology 1996, 64, 314–319. [CrossRef] [PubMed]
57. Arechaga, G.; Prieto, I.; Segarra, A.B.; Alba, F.; Ruiz-Larrea, M.B.; Ruiz-Sanz, J.I.; de Gasparo, M.; Ramirez, M. Dietary fatty acid
composition affects aminopeptidase activities in the testes of mice. Int. J. Androl. 2002, 25, 113–118. [CrossRef] [PubMed]
58. Zhou, Y.; Zhao, S.; Chen, K.; Hua, W.; Zhang, S. Predictive value of gamma-glutamyltransferase for ventricular arrhythmias and
cardiovascular mortality in implantable cardioverter-defibrillator patients. BMC Cardiovasc. Disord. 2019, 19, 129. [CrossRef]
59. Neuman, M.G.; Malnick, S.; Chertin, L. Gamma glutamyl transferase—An underestimated marker for cardiovascular disease and
the metabolic syndrome. J. Pharm. Pharm. Sci. 2020, 23, 65–74. [CrossRef]
60. Ruttmann, E.; Brant, L.J.; Concin, H.; Diem, G.; Rapp, K.; Ulmer, H.; Vorarlberg Health Monitoring and Promotion Program Study
Group. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: An epidemiological investigation in a
cohort of 163,944 Austrian adults. Circulation 2005, 112, 2130–2137. [CrossRef]
Biomedicines 2021, 9, 1149 15 of 16
61. Koenig, G.; Seneff, S. Gamma-Glutamyltransferase: A Predictive Biomarker of Cellular Antioxidant Inadequacy and Disease Risk.
Dis. Markers 2015, 2015, 818570. [CrossRef]
62. Kreutzer, F.; Krause, D.; Klaassen-Mielke, R.; Trampisch, H.J.; Diehm, C.; Rudolf, H. Gamma-glutamyl transferase as a risk
factor for mortality and cardiovascular events in older adults—Results from a prospective cohort study in a primary care setting
(getABI). Vasa 2019, 48, 313–319. [CrossRef]
63. Lee, D.S.; Evans, J.C.; Robins, S.J.; Wilson, P.W.; Albano, I.; Fox, C.S.; Wang, T.J.; Benjamin, E.J.; D’Agostino, R.B.; Vasan, R.S.
Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: The Framingham Heart Study.
Arterioscler. Thromb. Vasc. Biol. 2007, 27, 127–133. [CrossRef]
64. Ndrepepa, G.; Colleran, R.; Kastrati, A. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease.
Clin. Chim. Acta 2018, 476, 130–138. [CrossRef]
65. Greenberg, L.J. Fluorometric measurement of alkaline phosphatase and aminopeptidase activities in the order of 10-14 mole.
Biochem. Biophys. Res. Commun. 1962, 9, 430–435. [CrossRef]
66. Cheung, H.S.; Cushman, D.W. A soluble aspartate aminopeptidase from dog kidney. Biochim. Biophys. Acta 1971, 242, 190–193.
[CrossRef]
67. Tobe, H.; Kojima, F.; Aoyagi, T.; Umezawa, H. Purification by affinity chromatography using amastatin and properties of
aminopeptidase A from pig kidney. Biochim. Biophys. Acta 1980, 613, 459–468. [CrossRef]
68. Ramírez, M.; Prieto, I.; Banegas, I.; Segarra, A.B.; Alba, F. Neuropeptidases. Methods Mol. Biol. 2011, 789, 287–294. [CrossRef]
[PubMed]
69. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of
protein-dye binding. Anal. Biochem. 1976, 72, 248–254. [CrossRef]
70. Sá, J.M.; Barbosa, R.M.; Menani, J.V.; De Luca, L.A., Jr.; Colombari, E.; Almeida-Colombari, D.S. Cardiovascular and hidroelec-
trolytic changes in rats fed with high-fat diet. Behav. Brain Res. 2019, 373, 112075. [CrossRef]
71. Clifton, P.M.; Keogh, J.B. A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease. Nutr.
Metab. Cardiovasc. Dis. 2017, 27, 1060–1080. [CrossRef] [PubMed]
72. Arechaga, G.; Martínez, J.M.; Prieto, I.; Ramírez, M.J.; Sánchez, M.J.; Alba, F.; De Gasparo, M.; Ramírez, M. Serum aminopeptidase
A activity of mice is related to dietary fat saturation. J. Nutr. 2001, 131, 1177–1179. [CrossRef] [PubMed]
73. Summerhill, V.; Karagodin, V.; Grechko, A.; Myasoedova, V.; Orekhov, A. Vasculoprotective Role of Olive Oil Compounds via
Modulation of Oxidative Stress in Atherosclerosis. Front. Cardiovasc. Med. 2018, 5, 188. [CrossRef] [PubMed]
74. D’Agostino, R.; Barberio, L.; Gatto, M.; Muzzalupo, I.; Mandalà, M. Extra Virgin Olive Oil Phenols Dilate the Rat Mesenteric
Artery by Activation of BKCa2+ Channels in Smooth Muscle Cells. Molecules 2020, 25, 2601. [CrossRef]
75. Paknahad, Z.; Moosavian, S.P.; Mahdavi, R.; Rajabi, P. The effects of olive oil and cholesterol enriched diets on aortic fatty streak
development and lipid peroxidation in rabbits. Nutr. Health 2021, 18, 2601060211022260. [CrossRef]
76. Khan, S.A.; Sattar, M.Z.; Abdullah, N.A.; Rathore, H.A.; Abdulla, M.H.; Ahmad, A.; Johns, E.J. Obesity depresses baroreflex
control of renal sympathetic nerve activity and heart rate in Sprague Dawley rats: Role of the renal innervation. Acta Physiol.
2015, 214, 390–401. [CrossRef]
77. Segarra, A.B.; Prieto, I.; Martinez-Canamero, M.; Ruiz-Sanz, J.I.; Ruiz-Larrea, M.B.; De Gasparo, M.; Banegas, I.; Zorad, S.;
Ramirez-Sanchez, M. Enkephalinase activity is modified and correlates with fatty acids in frontal cortex depending on fish, olive
or coconut oil used in the diet. Endocr. Regul. 2019, 53, 59–64. [CrossRef]
78. Brilla, C.G.; Maisch, B.; Weber, K.T. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart
disease: In vivo and in vitro studies on collagen matrix regulation. Clin. Investig. 1993, 71, 35–41. [CrossRef]
79. Liu, T.; Wen, H.; Li, H.; Xu, H.; Xiao, N.; Liu, R.; Chen, L.; Sun, Y.; Song, L.; Bai, C.; et al. Oleic Acid Attenuates Ang II (Angiotensin
II)-Induced Cardiac Remodeling by Inhibiting FGF23 (Fibroblast Growth Factor 23) Expression in Mice. Hypertension 2020, 75,
680–692. [CrossRef]
80. Mascolo, A.; Sessa, M.; Scavone, C.; De Angelis, A.; Vitale, C.; Berrino, L.; Rossi, F.; Rosano, G.; Capuano, A. New and old roles of
the peripheral and brain renin-angiotensin-aldosterone system (RAAS): Focus on cardiovascular and neurological diseases. Int. J.
Cardiol. 2017, 227, 734–742. [CrossRef]
81. Marc, Y.; Boitard, S.E.; Balavoine, F.; Azizi, M.; Llorens-Cortes, C. Targeting Brain Aminopeptidase A: A New Strategy for the
Treatment of Hypertension and Heart Failure. Can. J. Cardiol. 2020, 36, 721–731. [CrossRef]
82. Weber, K.T.; Sun, Y.; Tyagi, S.C.; Cleutjens, J.P. Collagen network of the myocardium: Function, structural remodeling and
regulatory mechanisms. J. Mol. Cell. Cardiol. 1994, 26, 279–292. [CrossRef]
83. Harikrishnan, V.; Titus, A.S.; Cowling, R.T. Collagen receptor cross-talk determines α-smooth muscle actin-dependent collagen
gene expression in angiotensin II-stimulated cardiac fibroblasts. J. Biol. Chem. 2019, 294, 19723–19739. [CrossRef]
84. Manrique, C.; Habibi, J.; Aroor, A.R.; Sowers, J.R.; Jia, G.; Hayden, M.R.; Garro, M.; Martinez-Lemus, L.A.; Ramirez-Perez, F.I.;
Klein, T.; et al. Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female
mice. Cardiovasc. Diabetol. 2016, 15, 94. [CrossRef] [PubMed]
85. Gutiérrez-Cuevas, J.; Sandoval-Rodriguez, A.; Meza-Rios, A.; Monroy-Ramírez, H.C.; Galicia-Moreno, M.; García-Bañuelos, J.;
Santos, A.; Armendariz-Borunda, J. Molecular Mechanisms of Obesity-Linked Cardiac Dysfunction: An Up-Date on Current
Knowledge. Cells 2021, 10, 629. [CrossRef]
Biomedicines 2021, 9, 1149 16 of 16
86. Santana, A.B.; de Souza Oliveira, T.C.; Bianconi, B.L.; Barauna, V.G.; Santos, E.W.; Alves, T.P.; Silva, J.C.; Fiorino, P.; Borelli, P.;
Irigoyen, M.C.; et al. Effect of high-fat diet upon inflammatory markers and aortic stiffening in mice. BioMed Res. Int. 2014, 2014,
914102. [CrossRef]
87. Arendse, L.B.; Danser, A.; Poglitsch, M.; Touyz, R.M.; Burnett, J.C., Jr.; Llorens-Cortes, C.; Ehlers, M.R.; Sturrock, E.D. Novel
Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
Pharmacol. Rev. 2019, 71, 539–570. [CrossRef] [PubMed]
88. Cheng, H.C.; Abdel-Ghany, M.; Elble, R.C.; Pauli, B.U. Lung endothelial dipeptidyl peptidase IV promotes adhesion and
metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J. Biol. Chem. 1998, 273, 24207–24215. [CrossRef]
89. Wang, X.M.; Holz, L.E.; Chowdhury, S.; Cordoba, S.P.; Evans, K.A.; Gall, M.G.; Vieira de Ribeiro, A.J.; Zheng, Y.Z.; Levy, M.T.; Yu,
D.M.; et al. The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury. Immunol.
Cell. Biol. 2017, 95, 443–453. [CrossRef]
90. Oparil, S.; Schmieder, R.E. New approaches in the treatment of hypertension. Circ. Res. 2015, 116, 1074–1095. [CrossRef]
91. Stewart, M.H.; Lavie, C.J.; Ventura, H.O. Future pharmacological therapy in hypertension. Curr. Opin. Cardiol. 2018, 33, 408–415.
[CrossRef] [PubMed]
